For the latest updates on our ongoing response to COVID-19, please click here.

Pipeline

The impossible is simply what hasn’t been achieved yet. Gilead’s research and development program is focused on what’s next. We discover, identify and evaluate investigational compounds that show potential to advance the treatment of life-threatening diseases.

The safety and efficacy of the following investigational compounds or investigational uses of marketed products have not been established. These uses have not been approved by the U.S. Food and Drug Administration or other regulatory authorities.

Pipeline

Viral Diseases

  • Biktarvy

    HIV treatment pediatric1

    Phase 1
    Phase 2
    Phase 3
  • Capsid inhibitor (GS-6207)

    HIV HTE2

    Phase 1
    Phase 2
    Phase 3
  • Capsid inhibitor (GS-6207)

    HIV treatment naïve

    Phase 1
    Phase 2
    Phase 3
  • Vesatolimod (GS-9620, TLR-7 agonist)

    HIV cure

    Phase 1
    Phase 2
    Phase 3
  • Elipovimab (GS-9722, bNab)

    HIV cure

    Phase 1
    Phase 2
    Phase 3
  • Selgantolimod (GS-9688, TLR-8 agonist)

    HBV cure

    Phase 1
    Phase 2
    Phase 3
  • PD-L1 inhibitor (GS-4224)

    HBV cure

    Phase 1
    Phase 2
    Phase 3

1 Biktarvy HIV treatment pediatric label extension.

2 Registrational for heavily treatment-experienced (HTE) patients.

Inflammatory diseases

  • Filgotinib (GS-6034, JAK-1 inhibitor)

    Rheumatoid arthritis

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib (GS-6034, JAK-1 inhibitor)

    Ulcerative colitis

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib (GS-6034, JAK-1 inhibitor)

    Crohn's disease

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib (GS-6034, JAK-1 inhibitor)

    Psoriatic arthritis

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib (GS-6034, JAK-1 inhibitor)

    Ankylosing spondylitis

    Phase 1
    Phase 2
    Phase 3
  • Filgotinib (GS-6034, JAK-1 inhibitor)

    Uveitis

    Phase 1
    Phase 2
    Phase 3
  • TPL2 inhibitor (GS-4875)

    Ulcerative colitis

    Phase 1
    Phase 2
    Phase 3
  • GLPG-19721

    Osteoarthritis

    Phase 1
    Phase 2
    Phase 3
  • GLPG-05551

    Inflammatory diseases

    Phase 1
    Phase 2
    Phase 3
  • GLPG-33121

    Inflammatory diseases

    Phase 1
    Phase 2
    Phase 3
  • GLPG-39701

    Inflammatory diseases

    Phase 1
    Phase 2
    Phase 3
  • GLPG-36671

    Inflammatory diseases

    Phase 1
    Phase 2
    Phase 3

1 Optionable partner program.

Fibrotic Diseases

  • Cilofexor (GS-9674, FXR agonist)

    PSC

    Phase 1
    Phase 2
    Phase 3
  • GLPG-16901

    Idiopathic Pulmonary Fibrosis

    Phase 1
    Phase 2
    Phase 3
  • Cilofexor (FXR agonist)

    NASH

    Phase 1
    Phase 2
    Phase 3
  • Firsocostat (ACC inhibitor)

    NASH

    Phase 1
    Phase 2
    Phase 3
  • Selonsertib (ASK1 inhibitor) combinations

    NASH

    Phase 1
    Phase 2
    Phase 3
  • Selonsertib (GS-4997, ASK1 inhibitor)

    DKD

    Phase 1
    Phase 2
    Phase 3
  • GLPG-16901

    Systemic sclerosis

    Phase 1
    Phase 2
    Phase 3
  • GLPG-12052

    Idiopathic pulmonary fibrosis

    Phase 1
    Phase 2
    Phase 3

1 Optioned parter program.

2 Optionable partner program.

Oncology

  • KTE-X19

    MCL

    Phase 1
    Phase 2
    Phase 3
  • Axi-cel

    2L DLBCL

    Phase 1
    Phase 2
    Phase 3
  • Axi-cel

    Indolent NHL

    Phase 1
    Phase 2
    Phase 3
  • Axi-cel

    1L DLBCL

    Phase 1
    Phase 2
    Phase 3
  • Axi-cel

    DLBCL (+rituximab or lenalidomide)

    Phase 1
    Phase 2
    Phase 3
  • KTE-X19

    Adult ALL

    Phase 1
    Phase 2
    Phase 3
  • KTE-X19

    Pediatric ALL

    Phase 1
    Phase 2
    Phase 3
  • KTE-X19

    CLL

    Phase 1
    Phase 2
    Phase 3
  • Axi-cel

    DLBCL (utomilumab)

    Phase 1
    Phase 2
    Phase 3
  • KITE-718 (MAGE A3/A6)

    Solid tumor

    Phase 1
    Phase 2
    Phase 3
  • KITE-439 (HPV E7)

    Solid tumor

    Phase 1
    Phase 2
    Phase 3
  • Oral PD-L1 inhibitor (GS-4224)

    Solid tumor

    Phase 1
    Phase 2
    Phase 3
  • anti-CD73/TGFß TRAP (GS-1423)1

    Solid tumor

    Phase 1
    Phase 2
    Phase 3
  • Bi-specific mAb (AGEN1223)2,3,4

    Multiple

    Phase 1
    Phase 2
    Phase 3
  • Anti-CD137 mAb mAb (AGEN2373)3,4

    Multiple

    Phase 1
    Phase 2
    Phase 3

1 TME conditioning anti-CD73/TGFß TRAP bifunctional fusion protein (GS-1423).

2 Bi-specific mAb targeting immunosuppressive regulatory T cells (AGEN1223).

3 Exclusive option to license right from Agenus upon proof of concept data.

4 Optionable partner program. ALL - Acute lymphocytic leukemia. CLL - Chronic lymphocytic leukemia. DLBCL - Diffuse large B-cell lymphoma. iNHL - Indolent non-Hodgkin lymphoma. MCL - Mantle cell lymphoma. r/r - relapsed refractory. iNHL - Indolent non-Hodgkin lymphoma.